Trial Profile
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Astrocytoma; Cholangiocarcinoma; Glioma; Oligodendroglioma; Solid tumours
- Focus Therapeutic Use
- 01 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 15 Oct 2023 Results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
- 01 Aug 2023 Planned End Date changed from 31 Jul 2023 to 31 Jul 2024.